Assessment of erlotinib pharmacodynamics in tumors and skin of patients with head and neck cancer
Carcinoma, Squamous Cell
Head and Neck Neoplasms
The feasibility of obtaining serial evaluable biopsies of HNSCC was suboptimal. Nevertheless, erlotinib inhibited p-EGFR in HNSCC tumors, which appeared associated to clinical benefit, and induced p27 in biopsies of normal skin.